A small, ground­break­ing car­dio study push­es MyoKar­dia to a piv­otal show­down — shares soar

MyoKar­dia $MYOK has come up with the proof-of-con­cept ef­fi­ca­cy da­ta that the South San Fran­cis­co-based biotech was look­ing for in its small but po­ten­tial­ly ground­break­ing car­dio study. And now it will ex­plore by­pass­ing one el­e­ment in its de­vel­op­ment plan and see whether the FDA will sign up on a straight shot at a piv­otal study that could point the com­pa­ny down a straight path to the mar­ket­place.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER